Updated on 29 September 2015
Gene therapy pipeline in oncology gets strong
Singapore: Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development across all stages, highlights analysis firm GBI Research.
However, the majority of these remain in early steps of development, with 76 percent at either the discovery or preclinical stage.
According to the analysis firm, oncology, infectious diseases, genetic disorders, cardiovascular diseases and ophthalmological indications are the most active pipeline sectors, as well as the most widely studied in terms of the number of clinical trials.
There are 266 pipeline gene therapies in active development for oncology, more than double that of central nervous system disorders, which is the second-largest therapy area. Furthermore, oncology also accounted for 64 percent of gene therapy clinical trials between 1989 and 2012.
Mr Dominic Trewartha, managing analyst, GBI Research, said, "Oncology is the predominant area for gene therapy developments due to its high prevalence and genetically driven pathophysiology.